Semaglutide and tirzepatide are different medicines. Semaglutide acts at GLP-1 receptors; tirzepatide acts at GIP and GLP-1 receptors. The appropriate choice depends on the approved product, treatment goal, health history, tolerability, access, and the clinician’s assessment—not simply which name appears on a local price list.
Compare the named drug product
Wegovy contains semaglutide; Zepbound contains tirzepatide. Product labeling defines the approved uses, restrictions, and clinical warnings. A brand, active ingredient, compounded preparation, and a clinic’s program name are different identifiers. Ask which exact product a quote describes.
For the current range of indications and warnings, consult the current prescribing information with your clinician. An older approval announcement is useful background, but it is not a substitute for updated labeling.
Sources: Wegovy: current prescribing information · FDA: Zepbound approval announcement
What can a clinical trial tell you?
A 2025 randomized trial compared tirzepatide and semaglutide in adults with obesity without diabetes. Its results support a comparison in that studied population; they do not establish which drug is best for a particular Bradenton patient or validate every compounded preparation sold under the same ingredient name.
When a practice cites a weight-loss percentage, ask about the study population, treatment duration, products studied, and how the result was measured. An average outcome should not be presented as a personal guarantee.
Sources: Aronne et al., NEJM 2025: tirzepatide compared with semaglutide
A more useful side-by-side discussion
| Decision factor | Question for the clinician |
|---|---|
| Clinical purpose | Which labeled use or clinical rationale applies to me? |
| Medical history | Which warnings, contraindications, and interactions matter in my case? |
| Product source | Is this the approved product or a compounded preparation, and why? |
| Ongoing care | How will response and tolerability be assessed? |
| Access and cost | What happens if coverage, supply, or my circumstances change? |
Do not treat a compounded quote as a generic equivalent
Compounded drugs do not undergo the FDA approval process for safety, effectiveness, and quality. If compounding is proposed, ask why an approved product does not meet the individual medical need and how the prescriber and pharmacist have assessed that decision. Confirm the dispensing pharmacy rather than relying on an advertising label.
Sources: FDA: compounding questions and answers · FDA: concerns with unapproved GLP-1 drugs
Common questions
Are semaglutide and tirzepatide the same medicine?
No. They have different active ingredients and receptor activity. Product labeling and individual clinical circumstances matter when comparing them.
Can this comparison tell me which medicine to take?
No. It is a consultation guide. A clinician must assess suitability, alternatives, medical history, and follow-up.
Does the lowest monthly price identify the best option?
No. First establish which exact product is appropriate. Then compare the full cost of medication, evaluation, testing, and ongoing care.